Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet medical need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer. For more information about Mirati Therapeutics Inc., visit us at Mirati.com. Read our guidelines for interacting with Mirati on social media here: https://bit.ly/3lFIWB0.
View Top Employees from Mirati TherapeuticsWebsite | http://www.mirati.com |
Ticker | MRTX |
Revenue | $1 million |
Employees | 646 (646 on RocketReach) |
Founded | 2013 |
Address | 3545 Cray Ct, San Diego, California 92121, US |
Phone | (858) 332-3410 |
Category | Biotechnology Research, Pharmaceuticals, Healthcare |
Web Rank | 3 Million |
Keywords | mirati therapeutics, mirati, jessica corson mirati, kras g12c, james christensen (mirati therapeutics) |
Competitors | Celldex Therapeutics, G1 Therapeutics, Inc., Mersana Therapeutics, ORIC Pharmaceuticals Inc., Sorrento Therapeutics, Inc. |
SIC | 873, 87 |
NAICS | 541712, 541, 5417, 54, 33, 54171 |
Looking for a particular Mirati Therapeutics employee's phone or email?
The Mirati Therapeutics annual revenue was $1 million in 2023.
David Meek is the CEO of Mirati Therapeutics.
646 people are employed at Mirati Therapeutics.
Mirati Therapeutics is based in San Diego, California.
The NAICS codes for Mirati Therapeutics are [541712, 541, 5417, 54, 33, 54171].
The SIC codes for Mirati Therapeutics are [873, 87].